Pure Global AI
NCT06383793Recruiting

Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy in Totally Laparoscopic Total Gastrectomy

Northern Jiangsu People's HospitalClinicalTrials.govprocedure
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
overlap
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
Northern Jiangsu People's Hospital
Location
Yangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 30, 2025
Enrollment
100 participants
Primary outcome

1 year survival

Summary

As of now, although the safety of π-shaped anastomosis and the overlap method has been
 separately discussed in different contexts, there have been few studies considering a direct
 comparison of the results of these two methods.
 
 This article aims to explore the differences in the short-term therapeutic effects, surgical
 effectiveness, and safety between laparoscopic total gastrectomy with esophagogastrostomy
 using the overlap method and the π-shaped method. The goal is to provide new reference points
 for surgeons in the clinical decision-making process regarding the choice of anastomotic
 techniques during totally laparoscopic total gastrectomy.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06383793
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06383793 through Pure Global AI's free database. This phase not specified trial is sponsored by Northern Jiangsu People's Hospital and is currently Recruiting. The study focuses on Gastric Cancer. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.